Deloitte programme places Kymab among 50 fastest-growing technology companies in the UK
Kymab, the Cambridge-based antibodies-to-medicines company, has been recognised as one of the 50 fastest-growing technology companies in the UK.
Kymab won a place on the Deloitte 2017 UK Technology Fast 50.
The UK Fast 50 is one of the UK's foremost technology awards programmes. Now in its twentieth successful year, it is an acknowledgement of the 50 fastest-growing technology companies in the UK. The ranking is based on revenue growth over the last four years.
Kymab CFO Anne Hyland after being presented with the Deloitte UK Technology Fast 50 award
Kymab is using its unique antibody-development platform in therapeutic development and vaccine discovery. Its current targets include cancers, autoimmune and haematological disease and infectious disease, such as HIV and malaria.
David Cobb, lead partner for the Deloitte UK Technology Fast 50, said: "The Deloitte UK Technology Fast 50 gives great profile to technology companies and is internationally recognised as being one of the most important business awards in the sector.
"The Deloitte UK Technology Fast 50 awards are an opportunity for businesses to gain recognition for their successes and achievements over the last four years.
"The 50 fastest growing UK technology companies, as ranked by Deloitte, generated around £1bn in in total annual revenues in the year 2016/17, employing more than 9,000 people, including 1,800 in R&D alone.
"The awards are an opportunity for businesses to gain recognition for their successes and achievements. This year's ranking highlights the importance of being innovative, recruiting high-skilled talent and finding a niche product or service."
The Fast 50 ranking follows previous Kymab achievements, including nomination for the Emerging Star award at the London Stock Exchange techMARK mediscience annual event, which celebrates excellence within the life-sciences sector, and achieving the top ten of The Sunday Times Tech Track 'Ones to Watch'.
Notes to Editors
In this press release references to "Deloitte" are references to one or more of Deloitte Touche Tohmatsu Limited ("DTTL") a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms. Deloitte LLP is a subsidiary of Deloitte NWE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
About the Deloitte UK Technology Fast 50
The Deloitte UK Technology Fast 50 is one of the UK’s foremost technology award programmes. Now in its twentieth year, it is a ranking of the country’s 50 fastest-growing technology companies, based on revenue growth over the last four years. The UK Fast 50 awards are all about growth driven by leading intellectual property and are a celebration of innovation and entrepreneurship. The UK Technology Fast 50 is part of an international programme run by Deloitte and qualifying entrants of the UK Fast 50 will be put forward to the Deloitte Technology Fast 500 EMEA (Europe, Middle East and Africa) programme. Previous winners have come from across the UK, are both large and small, and included some of the most dynamic players in all areas of technology, from internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications.
For more information visit www.fast50.co.uk
Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immuno-oncology, auto-immunity, haematology, infectious disease and other areas.
For more information please see http://www.kymab.com